Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Free Cash Flow (2021 - 2025)

Prime Medicine (PRME) has disclosed Free Cash Flow for 5 consecutive years, with -$37.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow fell 514.32% year-over-year to -$37.5 million, compared with a TTM value of -$167.1 million through Dec 2025, down 28.38%, and an annual FY2025 reading of -$167.1 million, down 28.38% over the prior year.
  • Free Cash Flow was -$37.5 million for Q4 2025 at Prime Medicine, up from -$39.1 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $9.1 million in Q4 2024 and bottomed at -$68.5 million in Q1 2024.
  • Average Free Cash Flow over 5 years is -$35.9 million, with a median of -$39.0 million recorded in 2023.
  • The sharpest move saw Free Cash Flow surged 120.63% in 2024, then tumbled 514.32% in 2025.
  • Year by year, Free Cash Flow stood at -$13.9 million in 2021, then crashed by 46.34% to -$20.4 million in 2022, then crashed by 115.31% to -$43.9 million in 2023, then soared by 120.63% to $9.1 million in 2024, then crashed by 514.32% to -$37.5 million in 2025.
  • Business Quant data shows Free Cash Flow for PRME at -$37.5 million in Q4 2025, -$39.1 million in Q3 2025, and -$39.1 million in Q2 2025.